News

‘Best of Wubbzy: Fans’ Choice’ hits stores this fall

BY Allison Cerra

BEVERLY HILLS, Calif. — Anchor Bay Entertainment has introduced its first-ever collection of fan favorite "Wow! Wow! Wubbzy!" episodes on DVD.

The "Best of Wubbzy: Fans’ Choice" features seven of the most popular episodes as chosen by Facebook fans. Such episodes as "Follow The Leader," "The Wubbzy Shuffle," "Wubbzy The Star," "Tooth Or Dare," "Wubbzy’s Makeover" and "Wubbzy Bounces Back" and "Wubbzy The Hero," are showcased in the collection. "Wow! Wow! Wubbzy!" debuted on Nickelodeon’s Nick Jr. network in 2006.

The "Best of Wubbzy: Fans’ Choice" DVD will makes its retail debut on Sept. 18.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

June sales softer than expected at Target

BY Mike Troy

MINNEAPOLIS — Target reported a 2.1% same-store sales increase for the month of June that was toward the low end of the company’s expectations.

Despite June sales that were softer than expected, Target left its second-quarter profit forecast intact as the weaker-than-expected result offset a better-than-expected performance the previous month.

“Following better-than-expected performance in May, our June comparable-store sales were near the low end of our expected range,” said Gregg Steinhafel, Target’s chairman, president and CEO. “We believe these results, combined with our outlook for July, keep us on-track to deliver second quarter sales and adjusted EPS in line with the guidance we provided at the time of our first quarter earnings release.”

The company expects second quarter earnings adjusted to exclude expenses related to its entry in Canada to range from $1.04 to $1.14 and earning that include the Canadian costs to range from 94 centers to $1.04.

With a May comps increase of 4.4% and a June increase of 2.1% in the books, Target is calling for a July increase in the low to mid single digit range and expects to product a total second quarter same store sale increase of 3%.

The growth in July will likely come from some familiar sources, as was the case in June when the company said food grew at a low double digit pace and health and beauty increased in the mid single digits. Sales in the apparel and home categories increased in the low single-digit range while hardline categories advanced in the mid single-digits.

Customer traffic was flat during the month with all of the growth coming from increased transaction size.

While June results were less than planned and well below the June 2011 comp increase of 4.5%, the end point of the reporting period and the timing of the July 4 holiday likely had somewhat of an impact on sales. This year’s reporting period fell on Saturday, June 30 with July 4 falling on the following Wednesday, allowing shoppers more time to purchase Fourth of July related merchandise during the July reporting period. Conversely, the June reporting period the prior year ended on Saturday, July 2 and July 4 fell on the following Monday ensuring a larger percentage of Fourth of July sales likely fell in the June period.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

FDA orders unapproved oxycodone drugs off market

BY Alaric DeArment

SILVER SPRING, Md. — The Food and Drug Administration is asking companies to stop manufacturing and distributing unapproved drugs containing the painkiller oxycodone, the agency said Thursday.

The FDA said it issued the Federal Register notice as part of the Unapproved Drugs Initiative, a program it started in June 2006 to remove drugs from the market that have largely avoided regulatory scrutiny generally because their availability predates the agency’s current regulatory standards; some drugs removed from the market under the initiative in the past date back to the 1800s. All the drugs in the current notice are single-ingredient, immediate-release products with oxycodone, an opioid analgesic that the government considers a controlled substance because it has been linked to overdoses and abuse.

"It’s a high public health priority for FDA to remove these unapproved products from the market to minimize consumer exposure to drugs that may be unsafe, ineffective and of poor quality," FDA Center for Drug Evaluation and Research Office of Compliance acting director Ilisa Bernstein said. "Since FDA-approved versions of these oral dosage forms are available by prescription, there should be no negative impact on consumers as a result of this action and no disruptions to the drug supply."


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES